P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients.
Pierre Morel,Eric Lepage,Pauline Brice,Brigitte Dupriez,Marie-Françoise D'Agay,Pierre Fenaux,Bernard Gosselin,Francis Bauters,Christian Gisselbrecht +8 more
TL;DR: It is suggested that age and LDH are two important pretreatment prognostic factors for adult LBL, and that the optimal prognostic staging system remains a controversial issue.
Journal ArticleDOI
Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte
Rene-Olivier Casasnovas,Nicolas Mounier,Pauline Brice,Marine Divine,Franck Morschhauser,Jean Gabarre,Jean-Yves Blay,Laurent Voillat,Pierre Lederlin,Aspasia Stamatoullas,Jacques Bienvenu,Michel Guiguet,Liliane Intrator,Monique Grandjean,Josette Brière,Christophe Fermé,Gilles Salles +16 more
TL;DR: Plasma cytokine signature is sufficient to predict disease-related outcome in classical Hodgkin's lymphoma, and allows the identification of patients with very high risk of treatment failure, adding significant prognostic information to its predictive power.
Journal ArticleDOI
Molecular Analysis of Clonality in Castleman's Disease
Jean Soulier,Laurence Grollet,Eric Oksenhendler,Jean Michel Miclea,Patrice Cacoub,André Baruchel,Pauline Brice,Jean Pierre Clauvel,Marie Françoise D'Agay,Martine Raphael,François Sigaux +10 more
TL;DR: The clonality status of CD tissues in 34 patients, including 14 patients infected by the human immunodeficiency virus, is reported, and polyclonal VH-JH and V gamma-J gamma rearrangements were detected in the large majority of the cases, irrespective of pathologic subtypes, clinical forms, and HIV status.
Journal ArticleDOI
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Patrice Carde,Matthias Karrasch,Catherine Fortpied,Pauline Brice,Hussein M. Khaled,Olivier Casasnovas,Denis Caillot,Isabelle Gaillard,Serge Bologna,Christophe Fermé,Pieternella J. Lugtenburg,F. Morschhauser,Igor Aurer,Bertrand Coiffier,Ralph M. Meyer,Matthew Seftel,Max Wolf,Bengt Glimelius,Anna Sureda,Nicolas Mounier +19 more
TL;DR: ABVD8 and BEACopP4+4 resulted in similar EFS and OS in patients with high-risk advanced-stage HL, but BEACOPP4-4 did not demonstrate a favorable effectiveness or toxicity ratio compared with ABVD8, treatment burden, immediate and late toxicities, and associated costs must be considered.
Journal ArticleDOI
Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study
Steven Le Gouill,Sophie de Guibert,Lucie Planche,Pauline Brice,Jehan Dupuis,Guillaume Cartron,Achiel Van Hoof,Olivier Casasnovas,Emmanuel Gyan,Hervé Tilly,Christophe Fruchart,Eric Deconinck,Olivier Fitoussi,Lauris Gastaud,Vincent Delwail,Jean Gabarre,Remy Gressin,Michel Blanc,Charles Foussard,Gilles Salles +19 more
TL;DR: Regardless of front-line rituximab exposure, this study supports incorporating autologous stem cell transplantation in the therapeutic approach at first relapse for follicular lymphoma patients.